抗胆碱能负荷量表系统综述:异质性大且无金标准
该系统综述检索至2025年1月,纳入21项提出新或更新抗胆碱能负荷量表的研究,发现各量表收录药物27至217种,74%的高效价药物评分不一致,且无金标准量表;药物覆盖更广、考虑个体变异性的量表可能更具临床相关性。
要点
- 各量表收录药物数27至217种,74%的高效价药物评分不一致。
- 无金标准抗胆碱能负荷量表,地理来源和方法学影响异质性。
- 药物覆盖更广、考虑个体变异性的量表可能更具临床相关性。
核心结论
- 未确定金标准抗胆碱能负荷量表。
- 药物覆盖更广且考虑个体变异性的量表似乎更具临床相关性。
- 需要临床可及、通用的评分系统以应对抗胆碱能多重用药风险。
研究设计与样本
- 系统综述,检索截至2025年1月,纳入提出新或更新抗胆碱能负荷量表的研究。
- 从10969条记录中纳入21项研究,两名评价者独立筛选、提取数据并评估质量。
- 采用基于专家共识和量表开发原则的自定义工具进行质量评估,结果进行叙述性综合。
主要发现
- 各量表收录药物数从27到217种不等,74%的高效价药物评分不一致。
- 异质性受地理来源和方法学影响,文献回顾结合专家意见是最常见的开发方法。
- 剂量考虑等因素在各量表间不一致,影响临床相关性。
- 临床结局研究反映了这些不一致性。
关键数值与推荐
- 各量表收录药物数范围为27至217种。
- 74%的高效价药物评分不一致。
- 文献回顾后结合专家意见是最常见的量表开发方法。
临床怎么用
- 临床选择抗胆碱能负荷量表时需注意其药物覆盖范围和评分方法差异。
- 优先考虑药物覆盖更广且考虑个体变异性的量表可能更有利于风险评估。
- 应关注抗胆碱能多重用药患者的累积负荷风险。
局限性
- 未确定金标准量表,各量表间异质性大。
- 剂量考虑等评分因素不一致,影响临床相关性。
- 临床结局研究反映了量表间的不一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anticholinergic burden refers to the cumulative anticholinergic effect of all medications taken by an individual. Anticholinergic burden scales help identify patients at risk of anticholinergic adverse effects and guide prescribing. However, substantial variation exists between scales, with no gold standard identified. This variability may contribute to inconsistent risk assessment, suboptimal prescribing, and adverse outcomes. AIM: To systematically review available anticholinergic burden scales and their variability in medication lists, development strategies and scoring methods. As a secondary objective, the clinical outcomes associated with each scale were summarized. METHODS: A systematic search was conducted up to January 2025. Studies proposing novel or updated anticholinergic burden scales were included. Two reviewers independently performed study selection, data extraction, and quality assessment, using a custom tool based on expert consensus and principles of scale development. Findings were narratively synthesized. RESULTS: From 10,969 identified records, 21 studies met inclusion criteria. Medications included per scale ranged from 27 to 217, with 74% of high-potency drugs scored inconsistently. Variability was influenced by geographical origin and methodology, with literature review followed by expert opinion the most common method of development. Dosage consideration, among others, was inconsistent across scales, affecting clinical relevance. Clinical outcome studies reflected such inconsistencies. CONCLUSION: No gold standard anticholinergic burden scale was identified. Scales with broader drug coverage and accounting for individual variability appeared more clinically relevant. This review highlights the need for a clinically accessible, universal scoring system to better address the risks associated with anticholinergic polypharmacy.
引用
- Vennard O, Stewart C, Tolia M, et al. Anticholinergic Medication Burden Scales: A Systematic Review. J Am Geriatr Soc. 2026. PMID: 41730788. doi:10.1111/jgs.70352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。